Clinical Trial

IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with advanced Head/Neck Squamous cancer via intra-tumor or intra-artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-05-14; most recent amendment 2024-06-22.
Trial Details
NCT Number NCT03952065
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Head/Neck Neoplasm
Enrollment 200 participants
Start Date 2019-01-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2035-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-06-26